- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05827315
Incidence, Impact and Mechanisms of Perioperative Right VEntricular Dysfunction (IMPRoVE) (IMPRoVE)
Study Overview
Status
Conditions
Detailed Description
Heart attacks are relatively rare around the time of surgery, however by measuring blood markers of heart injury, recent research has revealed that heart injury which otherwise may not be immediately obvious is common. Whilst this type of heart injury appears to be strongly linked to patient outcomes (complications, recovery and survival), the causes and potential treatments for it are not well understood.
Our research group has specialist knowledge about the right-hand side of the heart (right-heart) - the side that pumps blood through the lungs - which is less commonly considered or studied around the time of surgery. We have shown in previous studies using magnetic resonance imaging (MRI) scans (specialised whole-body scans which use a magnet rather than X-rays), evidence of right-heart function deteriorating after surgery. We want to test the idea that some of the blood marker evidence of heart injury reflects injury to the right-heart and more importantly that we can protect the right-heart around the time of surgery, reducing injury and improving patient outcomes.
We will examine these questions in the following ways:
- With patients' permission, we will perform detailed ultrasound scans of the heart (echocardiography), and blood measurement of injury markers in 175 patients undergoing different types of major surgery. This will allow us to assess how common heart injury is (visible on scans of both sides of the heart), whether it makes any difference to a patient's outcome and whether it explains the changes seen in blood markers.
- We will ask 50 of these patients to undergo MRI scans of the heart pre- and post-operatively to allow us to identify evidence of injury resulting from heart inflammation around the time of surgery. Inflammation is common following surgery and occurs throughout a patient's body - we believe heart inflammation may be responsible for postoperative heart injury.
- In 10 of these patients, we will seek to obtain blood samples from vessels flowing into the heart (easily obtained from a simple blood sample) and from veins flowing out of the heart, obtained by passing a fine tube into the heart via blood vessels in a patient's neck under X-ray guidance. This will allow us to examine what happens to immune cells as they pass through the heart (i.e., are they activated by heart inflammation?) and better understand the meaning of the changes seen on MRI scans.
This study will give us a better understanding of which patients are likely to suffer heart injury around the time of surgery and how this injury occurs. With this knowledge, future patients could receive personalised treatment plans aimed at preventing injury and improving outcomes. We are not testing any new treatments in this study.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: Ben Shelley
- Phone Number: 0141 951 5000
- Email: Benjamin.Shelley@glasgow.ac.uk
Study Contact Backup
- Name: Philip McCall
- Phone Number: 0141 951 5000
- Email: Philip.mccall@glasgow.ac.uk
Study Locations
-
-
-
Clydebank, United Kingdom
- Golden Jubilee National Hospital
-
Contact:
- Ben Shelley
- Phone Number: 4293 0141 9515000
-
Principal Investigator:
- Ben Shelley
-
Glasgow, United Kingdom, G4 0SF
- Glasgow Royal Infirmary
-
Contact:
- Rachel Kearns
- Phone Number: 0141 211 4000
-
Principal Investigator:
- Rachel Kearns
-
Principal Investigator:
- Sonya McKinlay
-
Glasgow, United Kingdom, G51 4TF
- Queen Elizabeth University Hospital
-
Contact:
- Malcolm Watson
-
Principal Investigator:
- Malcolm Watson
-
Sub-Investigator:
- Indran Raju
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Main echocardiography study
Inclusion Criteria:
- Provision of informed consent
- Age >18 years
- Planned elective primary hip or knee joint replacement under spinal anaesthesia, major colorectal, major vascular surgery or surgery requiring one lung ventilation with or without lung resection
Exclusion Criteria:
- Pregnancy
- On-going participation in any investigational research which could undermine the scientific basis of the study
- Previous major surgery within three months prior to recruitment
- Previous participation in the IMPRoVE study at any time
- Inadequate comprehension of English resulting in inability to comply with instructions while undergoing investigations required for main study and sub-studies.
Additional exclusion criteria applicable to the T1 CMR sub-study includes:
- Atrial fibrillation at baseline
- Contraindication to cardiac magnetic resonance imaging (metal work in body etc)
- Contraindication to IV Gadolinium: acute or chronic renal failure, allergy to contrast
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Thoracic surgery cohort
35 patients undergoing thoracic surgery with lung resection and one lung ventilation under primarily general anaesthesia.
|
Echocardiography will be performed by BSE accredited echocardiographers in all 175 patients preoperatively and on day 2-4 postoperatively.
T1 CMR will be performed in 10 patients from each of the 5 surgical groups (50 patients in total) preoperatively and on day 2-4 postoperatively.
10 patients from the thoracic surgical group will undergo right heart catheterisation and coronary sinus blood sampling.
|
Upper gastrointestinal surgery cohort
35 patients undergoing upper gastrointestinal surgery with one lung ventilation under primarily general anaesthesia.
|
Echocardiography will be performed by BSE accredited echocardiographers in all 175 patients preoperatively and on day 2-4 postoperatively.
T1 CMR will be performed in 10 patients from each of the 5 surgical groups (50 patients in total) preoperatively and on day 2-4 postoperatively.
|
Colorectal surgery cohort
35 patients undergoing elective colorectal surgery under primarily general anaesthesia.
|
Echocardiography will be performed by BSE accredited echocardiographers in all 175 patients preoperatively and on day 2-4 postoperatively.
T1 CMR will be performed in 10 patients from each of the 5 surgical groups (50 patients in total) preoperatively and on day 2-4 postoperatively.
|
Vascular surgery cohort
35 patients undergoing elective open abdominal aortic surgery under primarily general anaesthesia.
|
Echocardiography will be performed by BSE accredited echocardiographers in all 175 patients preoperatively and on day 2-4 postoperatively.
T1 CMR will be performed in 10 patients from each of the 5 surgical groups (50 patients in total) preoperatively and on day 2-4 postoperatively.
|
Orthopaedic surgery cohort
35 patients undergoing elective primary hip or knee arthroplasty under spinal anaesthesia +/- sedation.
|
Echocardiography will be performed by BSE accredited echocardiographers in all 175 patients preoperatively and on day 2-4 postoperatively.
T1 CMR will be performed in 10 patients from each of the 5 surgical groups (50 patients in total) preoperatively and on day 2-4 postoperatively.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of postoperative Right ventricular dysfunction (RVD)
Time Frame: Echocardiography performed preoperatively and at day 2-4 postoperatively to measure change in RV function
|
RVD diagnosed by transthoracic echocardiography, defined as:
|
Echocardiography performed preoperatively and at day 2-4 postoperatively to measure change in RV function
|
Days alive and at home at 30 days postoperatively (DAH30)
Time Frame: Day 30 postoperatively
|
DAH30 is a continuous number between 0 and 30 which reflects, out of the 30 days following surgery, the total number of those days that a patient spends alive and at home.
If a patient dies within those 30 days, their value is set to 0. Data for DAH30 will be obtained by follow-up phone calls following the 30th postoperative day.
|
Day 30 postoperatively
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of postoperative left ventricular dysfunction (LVD)
Time Frame: Echocardiography performed preoperatively and at day 2-4 postoperatively to measure change in LV function
|
LVD classified as mild, moderately or severely impaired, defined by 2D-echocardiography derived biplane LV ejection fraction and the presence of wall motion abnormalities.
|
Echocardiography performed preoperatively and at day 2-4 postoperatively to measure change in LV function
|
Cardiac biomarkers
Time Frame: BNP and troponin measured preoperatively, on postoperative days 1 and 2 and on day of postoperative echocardiography (occurring on postoperative days 2-4).
|
Natriuretic peptides and high sensitivity troponin will be measured pre- and postoperatively.
|
BNP and troponin measured preoperatively, on postoperative days 1 and 2 and on day of postoperative echocardiography (occurring on postoperative days 2-4).
|
Cardiovascular complications
Time Frame: Day of postoperative echocardiography (day 2-4 postoperatively) and at discharge (on average one week).
|
Incidence of myocardial infarction, cardiac death, non-fatal cardiac arrest, coronary revascularisation, pulmonary embolus, deep-veined thrombosis, or new onset atrial fibrillation, and major adverse cardiac events
|
Day of postoperative echocardiography (day 2-4 postoperatively) and at discharge (on average one week).
|
Renal outcomes
Time Frame: Day of postoperative echocardiography (day 2-4 postoperatively) and at discharge (on average one week).
|
Kidney Disease Improving Global Outcome (KDIGO) classification of Acute Kidney Injury (AKI).
|
Day of postoperative echocardiography (day 2-4 postoperatively) and at discharge (on average one week).
|
Pulmonary outcomes
Time Frame: Day of postoperative echocardiography (day 2-4 postoperatively) and at discharge (on average one week).
|
Atelectasis, pneumonia, acute respiratory distress syndrome or pulmonary aspiration
|
Day of postoperative echocardiography (day 2-4 postoperatively) and at discharge (on average one week).
|
Infection Outcomes
Time Frame: Day of postoperative echocardiography (day 2-4 postoperatively) and at discharge (on average one week).
|
Fever and clinical suspicion of infection
|
Day of postoperative echocardiography (day 2-4 postoperatively) and at discharge (on average one week).
|
Neurological outcomes
Time Frame: Day of postoperative echocardiography (day 2-4 postoperatively) and at discharge (on average one week).
|
Delirium and stroke
|
Day of postoperative echocardiography (day 2-4 postoperatively) and at discharge (on average one week).
|
Sequential Organ Failure Assessment (SOFA) Score
Time Frame: Postoperative day 1,2, day of postoperative echocardiography in all patients. In patients admitted to HDU/ICU, SOFA score will be collected from postoperative day 0-7.
|
Score 0-24, where higher scores are a worse outcome.
|
Postoperative day 1,2, day of postoperative echocardiography in all patients. In patients admitted to HDU/ICU, SOFA score will be collected from postoperative day 0-7.
|
Fifteen-point Quality of Recovery Score (QoR-15)
Time Frame: Pre-operatively and day of postoperative echocardiography (day 2-4 postoperatively).
|
Fifteen questions assessing the quality of a patients recovery, each question is scored 0-10 with higher scores indicating a worse outcome.
|
Pre-operatively and day of postoperative echocardiography (day 2-4 postoperatively).
|
World Health Organisation Disability Assessment Schedule 2.0 (WHODAS 2.0)
Time Frame: Preoperatively, and at day 30, day 90, and one year postoperatively.
|
WHODAS 2.0 is a self administered questionnaire that assesses a patient's health and disability.
Twelve questions are scored 0-4, where a higher score indicates a worse outcome.
|
Preoperatively, and at day 30, day 90, and one year postoperatively.
|
EuroQoL Dimension Health Related Quality of Life Questionnaire (EQ-5D-5L)
Time Frame: Preoperatively, and at day 30, day 90, and one year postoperatively.
|
EQ-5D-5L is a self administered questionnaire that assesses 5 dimensions of a patient's quality of life.
Each dimension is scored 1-5, where a higher score indicates a worse outcome.
|
Preoperatively, and at day 30, day 90, and one year postoperatively.
|
Collaborators and Investigators
Investigators
- Principal Investigator: Ben Shelley, National Waiting Times Centre Board
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 22/ANAES/06
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Right Ventricular Dysfunction
-
University of ChicagoRecruitingHeart Failure | Right Ventricular Dysfunction | Right Ventricular FailureUnited States
-
Semmelweis University Heart and Vascular CenterCompletedRight Ventricular Dysfunction | Right Heart Failure | Right Ventricular Failure | Mitral Valve DiseaseHungary
-
University of MinnesotaRecruitingRight Ventricular DysfunctionUnited States
-
Montreal Heart InstituteOlivier Lachance, MD; Melissa Parent, MD; Patrick Tawil, MD; Etienne Couture, MD... and other collaboratorsCompletedRight Ventricular Dysfunction | Right Heart Failure | Heart; Dysfunction Postoperative, Cardiac SurgeryCanada
-
Centre Hospitalier Universitaire, AmiensRecruitingThoracic Surgery | Right VentricleFrance
-
Jewish General HospitalNot yet recruitingRight Ventricular Dysfunction | Left Ventricular Dysfunction | Quality of RecoveryCanada
-
Azienda Ospedaliera OO.RR. S. Giovanni di Dio e...RecruitingRight Ventricular DysfunctionItaly
-
University of GiessenGerman Research FoundationUnknownRight Ventricular DysfunctionGermany
-
University Hospital DubravaUnknownRight Ventricular Dysfunction | Left Ventricular Dysfunction | Biventricular FailureCroatia
-
Thomas Jefferson UniversityRecruiting
Clinical Trials on Echocardiography
-
Kang YanRecruiting
-
Lifetech Scientific (Shenzhen) Co., Ltd.RecruitingNon-valvular Atrial Fibrillation | Embolic StrokeChina
-
Assiut UniversityUnknownCORONARY ARTERY BYPASSEgypt
-
Assiut UniversityUnknownMyocardial Infarction | Left Ventricular Dysfunction | Echocardiography 2DEgypt
-
Milton S. Hershey Medical CenterCompletedEchocardiography, Transesophageal | Ventricular Function, RightUnited States
-
Weill Medical College of Cornell UniversityWithdrawn3D Transesophageal and Transthoracic EchocardiogramUnited States
-
Assiut UniversityNot yet recruiting
-
NHS Greater Glasgow and ClydeUniversity of Glasgow; Roche DiagnosticsRecruitingHeart Failure | Obesity | Heart Failure With Preserved Ejection FractionUnited Kingdom
-
Assiut UniversityNot yet recruiting
-
Ruijin HospitalRecruitingDiabetes Mellitus, Type 2 | Chronic Total Occlusion of Coronary ArteryChina